TScan Therapeutics, Inc.TCRXNASDAQ
Loading
Operating Cash Flow Growth AcceleratingAccelerating
Percentile Rank50
Studio
Year-over-Year Change

Year-over-year operating cash flow growth rate

Percentile
P50
Within normal range
vs 5Y Ago
-0.3x
Contraction
Streak
1 yr
Consecutive growthAccelerating
PeriodValue
2025-22.10%
2024-80.62%
20237.74%
2022-36.62%
2021-1510.22%
202075.86%
20190.00%